<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7454a78a-b80e-4301-8e7b-404a9c0caeaf"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">URSODIOL TABLETS</content>
      <content styleCode="bold">, 250 mg and 500 mg </content>
      <content styleCode="bold">safely and effectively. </content>
      <content styleCode="bold">See full prescribing information for </content>
      <content styleCode="bold">URSODIOL TABLETS</content>
      <content styleCode="bold">, 250 mg and 500 mg</content>
      <content styleCode="bold"> tablets</content>
      <content styleCode="bold">.</content>
      <br/>
      <content styleCode="bold">     </content>
      <br/>
      <content styleCode="bold">URSODIOL TABLETS</content>
      <content styleCode="bold">, 250 mg</content>
      <content styleCode="bold">, for oral use</content>
      <br/>
      <content styleCode="bold">URSODIOL TABLETS</content>
      <content styleCode="bold">, 500 mg</content>
      <content styleCode="bold">, for oral use</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1997</content>
      <br/>
   </title>
   <effectiveTime value="20180629"/>
   <setId root="0a7c1ae6-4878-43e7-9026-073f74af64c0"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="119723554" root="1.3.6.1.4.1.519.1"/>
            <name>Actavis Pharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="af67a731-d6bb-46db-8e64-d331d96fd00d"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20241001"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0591-2998" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ursodiol</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ursodiol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="724L30Y2QR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>URSODIOL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="724L30Y2QR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>URSODIOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4W5IH7FLNY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBUTYL SEBACATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="936JST6JCN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="BBX060AN9V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROGEN PEROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0591-2998-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19971210"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020675" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" displayName="NDA authorized generic" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19971210"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">URS785</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Elliptical; Biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0591-3005" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ursodiol</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ursodiol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="724L30Y2QR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>URSODIOL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="724L30Y2QR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>URSODIOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4W5IH7FLNY" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBUTYL SEBACATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R12CBM0EIZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARNAUBA WAX</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="936JST6JCN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="BBX060AN9V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROGEN PEROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0591-3005-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19971210"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA020675" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" displayName="NDA authorized generic" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19971210"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">URS790</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Elliptical; Biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1__INDICATIONS">
               <id root="1809a8f3-85f3-43eb-8e47-fac91fc4eb91"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
		     
	<content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>
		     
	Ursodiol tablets, USP 250 mg and 500 mg are indicated for the treatment of patients with primary biliary cirrhosis (PBC).</paragraph>
               </text>
               <effectiveTime value="20180629"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ursodiol tablets, USP 250 mg and 500 mg are bile acids indicated for the treatment of patients with primary biliary cirrhosis (<linkHtml href="#_1__INDICATIONS">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="a0e33dc9-600e-4995-8120-69d00f125256"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
		     
	<content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20180629"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Recommended adult dosage: 13-15 mg/kg/day administered in two to four divided doses with food (<linkHtml href="#_2_1__">2.1</linkHtml>) <br/>
                           </item>
                           <item>Scored ursodiol tablets, USP 500 mg: scored tablet can be broken in halves to provide recommended dosage (<linkHtml href="#_2_3_Scoring_the">2.3</linkHtml>, <linkHtml href="#_16_2_Ursodiol_tablets_">16.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1__">
                     <id root="0a5018af-39c0-4eba-aace-117ea11f7e42"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1</content>
		     
	<content styleCode="bold">General Dosing Information</content>
                     </title>
                     <text>
                        <paragraph>
		     
	The recommended adult dosage for ursodiol tablets, USP 250 and 500 mg in the treatment of PBC is 13-15 mg/kg/day administered in two to four divided doses with food. Dosing regimen should be adjusted according to each patient’s need at the discretion of the physician. </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="df134f5d-407b-47df-b04b-f84ff52e2eb0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2</content>
		     
	<content styleCode="bold">Liver Function Tests</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Liver function tests (γ-GT, alkaline phosphatase, AST, ALT) and bilirubin levels should be monitored every month for three months after start of therapy, and every six months thereafter <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_1_Abnormal_Liver">Warnings and Precautions (5.1)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3_Scoring_the">
                     <id root="86d8213c-d0f5-4837-a2b2-55b3622d3f16"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3</content>
		     
	<content styleCode="bold">Scoring the </content>
                        <content styleCode="bold">Ursodiol </content>
                        <content styleCode="bold">tablet</content>
                        <content styleCode="bold">s, USP 500 mg</content>
                     </title>
                     <text>
                        <paragraph>
		     
	The ursodiol tablets, USP 500 mg scored tablet can be broken in halves to provide recommended dosage. </paragraph>
                        <paragraph>
		     
	To break ursodiol tablets, USP 500 mg scored tablet easily, place the tablet on a flat surface with the scored section on top.  Hold the tablet with your thumbs placed close to the scored part of the tablet (groove). Then apply gentle pressure and snap the tablet segments apart (segments breaking incorrectly should not be used). The segments should be washed down unchewed, with water, keeping the segments in the mouth can reveal a bitter taste.  Due to the bitter taste, segments should be stored separately from whole tablets. <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_16_2_Ursodiol_tablets_">How Supplied/Storage and Handling (16.2)</linkHtml>
                           </content>
                           <content styleCode="italics">]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3__DOSAGE">
               <id root="7fb19027-48a9-4c70-a280-ddfe70cf6902"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
		     
	<content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Ursodiol tablets, USP: 250 mg tablet<br/>
                     </item>
                     <item>Ursodiol tablets, USP: 500 mg scored tablet</item>
                  </list>
               </text>
               <effectiveTime value="20180629"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Ursodiol tablets, USP 250 mg: 250 mg tablet (<linkHtml href="#_3__DOSAGE">3</linkHtml>)<br/>
                           </item>
                           <item>Ursodiol tablets, USP 500 mg: 500 mg scored tablet (<linkHtml href="#_3__DOSAGE">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4__CONTRAINDICATIONS">
               <id root="16488598-b434-4991-8962-934395adc6f6"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
		     
	<content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>
		     
	Patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation.</paragraph>
               </text>
               <effectiveTime value="20180629"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with complete biliary obstruction and known hypersensitivity or intolerance to ursodiol or any of the components of the formulation (<linkHtml href="#_4__CONTRAINDICATIONS">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_5_WARNINGS_AND">
               <id root="01b6b521-29dc-4ea0-a782-a16cb0035e50"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
		     
	<content styleCode="bold">WARNINGS AND PRECAUTIONS</content>
               </title>
               <text>
                  <paragraph>
		     
	Patients with variceal bleeding, hepatic encephalopathy, ascites or in need of an urgent liver transplant, should receive appropriate specific treatment.</paragraph>
               </text>
               <effectiveTime value="20180629"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Patients with variceal bleeding, hepatic encephalopathy, ascites or in need of an urgent liver transplant, should receive appropriate specific treatment (<linkHtml href="#_5_WARNINGS_AND">5</linkHtml>).<br/>
                           </item>
                           <item>Liver function tests (γ-GT, alkaline phosphatase, AST, ALT) and bilirubin level should be monitored. Treatment discontinuation should be considered if parameters increase to a level considered clinically significant in patients with stable historical liver function test levels (<linkHtml href="#_5_WARNINGS_AND">5</linkHtml>).<br/>
                           </item>
                           <item>Caution should be exercised to maintain patients’ bile flow (<linkHtml href="#_5_WARNINGS_AND">5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Abnormal_Liver">
                     <id root="d901ecbd-0d03-4b7b-b28f-e5ed989b3af8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1</content>
		     
	<content styleCode="bold">Abnormal Liver Function Tests</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Liver function tests (γ-GT, alkaline phosphatase, AST, ALT) and bilirubin levels should be monitored every month for three months after start of therapy, and every six months thereafter. This monitoring will allow the early detection of a possible deterioration of the hepatic function. Treatment discontinuation should be considered if the above parameters increase to a level considered clinically significant in patients with stable historical liver function test levels.</paragraph>
                        <paragraph>
		     
	Caution has to be exercised to maintain the bile flow of the patients taking ursodiol.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_6_ADVERSE_REACTIONS">
               <id root="16f0959f-d4c8-4246-bae2-0d606bbe4d06"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
		     
	<content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <effectiveTime value="20180629"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions reported with the use of ursodiol during worldwide postmarketing and clinical experience (≥1%) are, in alphabetical order: abdominal discomfort, abdominal pain, alopecia, diarrhea, nausea, pruritus, and rash (<linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="93764a8a-bb40-407f-8d39-04d241d0ed8b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
		     
	<content styleCode="bold">Clinical Studies Experience</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>
		     
	The following table summarizes the adverse reactions observed in two placebo-controlled clinical trials. </paragraph>
                        <table>
                           <col width="210"/>
                           <col width="101"/>
                           <col width="109"/>
                           <col width="109"/>
                           <col width="109"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold italics">ADVERSE REACTIONS</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold italics">VISIT AT 12 MONTHS</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold italics">VISIT AT 24 MONTHS </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "> </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">UDCA<br/>n (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Placebo<br/>n (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">UDCA<br/>n (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Placebo<br/>n (%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Diarrhea </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (1.32)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Elevated creatinine </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (1.32)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Elevated blood glucose </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (1.18)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (1.32)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Leukopenia </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2 (2.63)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Peptic ulcer </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (1.32)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Skin rash </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2 (2.63)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Thrombocytopenia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">---</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 (1.32)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">--- </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="5">Note: Those adverse reactions occurring at the same or higher incidence in the placebo as in the UDCA group have been deleted from this table (this includes diarrhea and thrombocytopenia at 12 months, nausea/vomiting, fever and other toxicity). <br/>UDCA = Ursodeoxycholic acid = Ursodiol </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
		     
	In a randomized, cross-over study in sixty PBC patients, seven patients (11.6%) reported nine adverse reactions: abdominal pain and asthenia (1 patient), nausea (3 patients), dyspepsia (2 patients) and anorexia and esophagitis (1 patient each). One patient on the twice a day regimen (total dose 1000 mg) withdrew due to nausea. All of these nine adverse reactions except esophagitis were observed with the twice a day regimen at a total daily dose of 1000 mg or greater. However, an adverse reaction may occur at any dose.  </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c1c3865e-6307-41f2-8e05-e690de447d17"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
		     
	<content styleCode="bold">Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>
		     
	The following adverse reactions, presented by system organ class in alphabetical order, have been identified during postapproval use of ursodiol. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Gastrointestinal disorders</content>: abdominal discomfort, abdominal pain, constipation, diarrhea, dyspepsia, nausea, vomiting.<br/>
                           </item>
                           <item>
                              <content styleCode="italics">General disorders and administration site conditions</content>: malaise, peripheral edema, pyrexia.<content styleCode="italics"> </content>
                              <br/>
                           </item>
                           <item>
                              <content styleCode="italics">Hepatobiliary disorders</content>:<content styleCode="italics"> </content>jaundice (or aggravation of pre-existing jaundice). <br/>
                           </item>
                           <item>
                              <content styleCode="italics">Immune System Disorders</content>: Drug hypersensitivity to include facial edema, urticaria, angioedema and laryngeal edema. <br/>
                           </item>
                           <item>
                              <content styleCode="italics">Abnormal Laboratory Tests: </content>ALT increased, AST increased, blood alkaline phosphatase increased, blood bilirubin increased, γ-GT increased, hepatic enzyme increased, liver function test abnormal, transaminases increased. <br/>
                           </item>
                           <item>
                              <content styleCode="italics">Musculoskeletal and connective tissue disorders</content>: myalgia<br/>
                           </item>
                           <item>
                              <content styleCode="italics">Nervous system disorders</content>: dizziness, headache.<br/>
                           </item>
                           <item>
                              <content styleCode="italics">Respiratory, thoracic and mediastinal disorders</content>: cough.<br/>
                           </item>
                           <item>
                              <content styleCode="italics">Skin and subcutaneous tissue disorder</content>: alopecia, pruritus, rash.</item>
                        </list>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_7_Drug_Interactions">
               <id root="5d126ae6-7f38-4d0f-9b2d-544feb8b23be"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7</content>
		     
	<content styleCode="bold">Drug Interactions</content>
               </title>
               <effectiveTime value="20180629"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Bile Acid Sequestering Agents: May interfere with the action of ursodiol tablets, USP 250 mg and 500 mg by reducing its absorption (<linkHtml href="#_7_1_Bile_Acid">7.1</linkHtml>)<br/>
                           </item>
                           <item>Aluminum-based Antacids: May interfere with the action of ursodiol tablets, USP 250 mg and 500 mg by reducing its absorption (<linkHtml href="#_7_2_Aluminum_based_Antacids">7.2</linkHtml>)<br/>
                           </item>
                           <item>Drugs that alter the metabolism of lipids or induce cholestasis may interfere with the action of ursodiol tablets, USP 250 mg and 500 mg (<linkHtml href="#_7_3_Drugs_Affecting">7.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7_1_Bile_Acid">
                     <id root="848f2770-040f-416a-bc61-71e206307e40"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1</content>
		     
	<content styleCode="bold">Bile Acid Sequestering Agents</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Bile acid sequestering agents such as cholestyramine and colestipol may interfere with the action of ursodiol tablets, USP 250 mg and 500 mg by reducing its absorption. </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_2_Aluminum_based_Antacids">
                     <id root="2bc67dbe-adb1-46a3-b833-e47b773b15b2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2</content>
		     
	<content styleCode="bold">Aluminum-based Antacids</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Aluminum-based antacids have been shown to adsorb bile acids <content styleCode="italics">in vitro </content>and may be expected to interfere with ursodiol tablets, USP 250 mg and 500 mg in the same manner as the bile acid sequestering agents. </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_3_Drugs_Affecting">
                     <id root="773acf26-9acd-4c72-bc0b-b41e8706f583"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.3</content>
		     
	<content styleCode="bold">Drugs Affecting Lipid Metabolism</content>
                     </title>
                     <text>
                        <paragraph>Estrogens, oral contraceptives, and clofibrate (and perhaps other lipid-lowering drugs) increase hepatic cholesterol secretion and encourage cholesterol gallstone formation and hence may counteract the effectiveness of ursodiol tablets, USP 250 mg and 500 mg. </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3db56562-1661-4a00-b7e9-bb2a4c8c3e04"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
		     
	<content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20180629"/>
               <component>
                  <section>
                     <id root="e5da5b9e-0b24-4b66-8598-373d0aa6faea"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
		     
	<content styleCode="bold">Pregnancy </content>
                     </title>
                     <text>
                        <paragraph>
		     
	Reproduction studies have been performed in pregnant rats at oral doses up to 22 times the recommended maximum human dose (based on body surface area) and in pregnant rabbits at oral doses up to 7 times the recommended maximum human dose (based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to ursodiol.</paragraph>
                        <paragraph>There are no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="22ec0795-6269-4d06-bc59-8484573ef816"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34080-2" displayName="NURSING MOTHERS SECTION"/>
                     <title>
                        <content styleCode="bold">8.3</content>
		     
	<content styleCode="bold">Nursing Mothers </content>
                     </title>
                     <text>
                        <paragraph>
		     
	It is not known whether ursodiol is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ursodiol tablets, USP 250 mg and 500 mg are administered to a nursing mother. </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="70e62113-9420-457a-be91-1a13f0793f51"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
		     
	<content styleCode="bold">Pediatric Use</content>
                        <content styleCode="bold"> </content>
                     </title>
                     <text>
                        <paragraph>
		     
	The safety and effectiveness of ursodiol tablets, USP 250 mg and 500 mg in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="6f954ed6-6fd5-4ec8-b342-3bf0f1764fe3"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10</content>
		     
	<content styleCode="bold">OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>
		     
	There have been no reports of accidental or intentional overdosage with ursodiol. Single oral doses of ursodiol at 10 g/kg in mice and dogs, and 5 g/kg in rats were not lethal. A single oral dose of ursodiol at 1.5 g/kg was lethal in hamsters. Symptoms of acute toxicity were salivation and vomiting in dogs, and ataxia, dyspnea, ptosis, agonal convulsions and coma in hamsters.</paragraph>
               </text>
               <effectiveTime value="20180629"/>
            </section>
         </component>
         <component>
            <section>
               <id root="7edd0554-6683-4f08-8f62-a7a8929f6bdc"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
		     
	<content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>
		     
	Ursodiol tablets, USP 250 mg is available as a film-coated tablet for oral administration. Ursodiol tablets, USP 500 mg is available as a scored film-coated tablet for oral administration. </paragraph>
                  <paragraph>Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the biles of certain species of bears.  It is a bitter-tasting white powder consisting of crystalline particles freely soluble in ethanol and glacial acetic acid, slightly soluble in chloroform, sparingly soluble in ether, and practically insoluble in water.  The chemical name of ursodiol is 3α,7ß-dihydroxy-5ß-cholan-24-oic (C<sub>24</sub>H<sub>40</sub>O<sub>4</sub>). Ursodiol has a molecular weight of 392.56.  Its structure is shown below.</paragraph>
                  <paragraph> <renderMultiMedia referencedObject="MM03000001"/>
                  </paragraph>
                  <paragraph>
		     
	</paragraph>
                  <paragraph>Inactive ingredients: microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate, ethylcellulose, dibutyl sebacate, carnauba wax, hydroxypropyl methylcellulose, PEG 3350, PEG 8000, cetyl alcohol, sodium lauryl sulfate and hydrogen peroxide.</paragraph>
               </text>
               <effectiveTime value="20180629"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>The structure is shown below, Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the biles of certain species of bears.  It is a bitter-tasting white powder consisting of crystalline particles freely soluble in ethanol and glacial acetic acid, slightly soluble in chloroform, sparingly soluble in ether, and practically insoluble in water.  The chemical name of ursodiol is 3α,7ß-dihydroxy-5ß-cholan-24-oic (C24H40O4). Ursodiol has a molecular weight of 392.56.  </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ursodiol-tablets-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="87bdbb21-b9ef-4256-aac8-5e9e0ba6923c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
		     
	<content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20180629"/>
               <component>
                  <section>
                     <id root="25ac8085-961d-457c-8208-59241c95346e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
		     
	<content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Ursodiol, a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total human bile acid pool. Oral administration of ursodiol increases this fraction in a dose related manner, to become the major biliary acid, replacing/displacing toxic concentrations of endogenous hydrophobic bile acids that tend to accumulate in cholestatic liver disease.</paragraph>
                        <paragraph>
		     
	In addition to the replacement and displacement of toxic bile acids, other mechanisms of action include cytoprotection of the injured bile duct epithelial cells (cholangiocytes) against toxic effects of bile acids, inhibition of apoptosis of hepatocytes, immunomodulatory effects, and stimulation of bile secretion by hepatocytes and cholangiocytes.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="0a178242-cce0-4bb9-811d-36a3cb1f8aad"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2</content>
		     
	<content styleCode="bold">Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Lithocholic acid, when administered chronically to animals, causes cholestatic liver injury that may lead to death from liver failure in certain species unable to form sulfate conjugates. Ursodiol is 7-dehydroxylated more slowly than chenodiol. For equimolar doses of ursodiol and chenodiol, steady state levels of lithocholic acid in biliary bile acids are lower during ursodiol administration than with chenodiol administration. Humans and chimpanzees can sulfate lithocholic acid. Although liver injury has not been associated with ursodiol therapy, a reduced capacity to sulfate may exist in some individuals.  </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8fd13767-becc-43db-9b7a-2c44266148a6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
		     
	<content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Ursodiol (UDCA) is normally present as a minor fraction of the total bile acids in humans (about 5%).  Following oral administration, the majority of ursodiol is absorbed by passive diffusion and its absorption is incomplete. Once absorbed, ursodiol undergoes hepatic extraction to the extent of about 50% in the absence of liver disease. As the severity of liver disease increases, the extent of extraction decreases. In the liver, ursodiol is conjugated with glycine or taurine, then secreted into bile.  These conjugates of ursodiol are absorbed in the small intestine by passive and active mechanisms. The conjugates can also be deconjugated in the ileum by intestinal enzymes, leading to the formation of free ursodiol that can be reabsorbed and reconjugated in the liver. Nonabsorbed ursodiol passes into the colon where it is mostly 7-dehydroxylated to lithocholic acid. Some ursodiol is epimerized to chenodiol (CDCA) via a 7-oxo intermediate. Chenodiol also undergoes 7-dehydroxylation to form lithocholic acid. These metabolites are poorly soluble and excreted in the feces. A small portion of lithocholic acid is reabsorbed, conjugated in the liver with glycine, or taurine and sulfated at the 3 position. The resulting sulfated lithocholic acid conjugates are excreted in bile and then lost in feces. </paragraph>
                        <paragraph>
		     
	In healthy subjects, at least 70% of ursodiol (unconjugated) is bound to plasma protein. No information is available on the binding of conjugated ursodiol to plasma protein in healthy subjects or PBC patients. Its volume of distribution has not been determined, but is expected to be small since the drug is mostly distributed in the bile and small intestine. Ursodiol is excreted primarily in the feces. With treatment, urinary excretion increases, but remains less than 1% except in severe cholestatic liver disease. </paragraph>
                        <paragraph>
		     
	During chronic administration of ursodiol, it becomes a major biliary and plasma bile acid. At a chronic dose of 13 to 15 mg/kg/day, ursodiol constitutes 30-50% of biliary and plasma bile acids.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="0982e54a-01bb-4a01-abda-9b4210438f61"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
		     
	<content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20180629"/>
               <component>
                  <section>
                     <id root="e576030b-392d-40c8-a74c-8a91fb57dca9"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
		     
	<content styleCode="bold">Carcinogenesis</content>
                        <content styleCode="bold">, Mutagen</content>
                        <content styleCode="bold">esis</content>
                        <content styleCode="bold">,</content>
                        <content styleCode="bold"> Impairment of</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Fertility </content>
                     </title>
                     <text>
                        <paragraph>
		     
	In two 24-month oral carcinogenicity studies in mice, ursodiol at doses up to 1,000 mg/kg/day (3,000 mg/m<sup>2</sup>/day) was not tumorigenic. Based on body surface area, for a 50 kg person of average height (1.46 m<sup>2</sup> body surface area), this dose represents 5.4 times the recommended maximum clinical dose of 15 mg/kg/day (555 mg/m<sup>2</sup>/day). </paragraph>
                        <paragraph>
		     
	In a two-year oral carcinogenicity study in Fischer 344 rats, ursodiol at doses up to 300 mg/kg/day (1,800 mg/m<sup>2</sup>/day, 3.2 times the recommended maximum human dose based on body surface area) was not tumorigenic. </paragraph>
                        <paragraph>
		     
	In a life-span (126-138 weeks) oral carcinogenicity study, Sprague-Dawley rats were treated with doses of 33 to 300 mg/kg/day, 0.4 to 3.2 times the recommended maximum human dose based on body surface area. Ursodiol produced a significantly (p<content styleCode="underline">&lt;</content>0.5, Fisher's exact test) increased incidence of pheochromocytomas of the adrenal medulla in females of the highest dose group. </paragraph>
                        <paragraph>
		     
	In 103-week oral carcinogenicity studies of lithocholic acid, a metabolite of ursodiol, doses up to 250 mg/kg/day in mice and 500 mg/kg/day in rats did not produce any tumors. In a 78-week rat study, intrarectal instillation of lithocholic acid (1 mg/kg/day) for 13 months did not produce colorectal tumors. A tumor-promoting effect was observed when it was administered after a single intrarectal dose of a known carcinogen N-methyl-N'-nitro-N-nitrosoguanidine. On the other hand, in a 32-week rat study, ursodiol at a daily dose of 240 mg/kg (1,440 mg/m<sup>2</sup>, 2.6 times the maximum recommended human dose based on body surface area) suppressed the colonic carcinogenic effect of another known carcinogen azoxymethane. </paragraph>
                        <paragraph>
		     
	Ursodiol was not genotoxic in the Ames test, the mouse lymphoma cell (L5178Y, TK+/-) forward mutation test, the human lymphocyte sister chromatid exchange test, the mouse spermatogonia chromosome aberration test, the Chinese hamster micronucleus test and the Chinese hamster bone marrow cell chromosome aberration test. </paragraph>
                        <paragraph>
		     
	Ursodiol at oral doses of up to 2,700 mg/kg/day (16,200 mg/m<sup>2</sup>/day, 29 times the recommended maximum human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="fa1237c2-304d-4679-84e9-04fa62c8030d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
		     
	<content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <effectiveTime value="20180629"/>
               <component>
                  <section>
                     <id root="209ced4a-ccc3-4889-a24e-4d6e2b9b8b18"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1</content>
		     
	<content styleCode="bold">Efficacy of Ursodeoxycholic Acid A</content>
                        <content styleCode="bold">dministered at 13 to 15 </content>
                        <content styleCode="bold">mg/kg/day in 3 or 4 Divided Doses to PBC Patients</content>
                     </title>
                     <text>
                        <paragraph>
		     
	A U.S., multicenter, randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy of ursodeoxycholic acid at a dose of 13 to 15 mg/kg/day, administered in 3 or 4 divided doses in 180 patients with PBC (78% received four times a day dosage). Upon completion of the double-blind portion, all patients entered an open-label active treatment extension phase. </paragraph>
                        <paragraph>
		     
	Treatment failure, the main efficacy endpoint measured during this study, was defined as death, need for liver transplantation, histologic progression by two stages or to cirrhosis, development of varices, ascites or encephalopathy, marked worsening of fatigue or pruritus, inability to tolerate the drug, doubling of serum bilirubin and voluntary withdrawal. After two years of double-blind treatment, the incidence of treatment failure was significantly (p&lt;0.01) reduced in the ursodiol tablets, USP 250 mg group (20 of 86 (23%) as compared to the placebo group (40 of 86 (47%). Time to treatment failure, which excluded doubling of serum bilirubin and voluntary withdrawal, was also significantly (p&lt;0.001) delayed in the ursodiol tablets, USP 250 mg treated group (n=86, 803.8±24.9 d vs. 641.1±24.4 d for the placebo group (n=86) on average) regardless of either histologic stage or baseline bilirubin levels (&gt;1.8 or <content styleCode="underline">&lt;</content>1.8 mg/dL). </paragraph>
                        <paragraph>
		     
	Using a definition of treatment failure, which excluded doubling of serum bilirubin and voluntary withdrawal, time to treatment failure was significantly delayed in the ursodiol tablets, USP 250 mg group. In comparison with placebo, treatment with ursodiol tablets, USP 250 mg resulted in a significant improvement in the following serum hepatic biochemistries when compared to baseline: total bilirubin, SGOT, alkaline phosphatase and IgM. </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="b77fedd6-6fa3-4922-8540-3e2e60c64513"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.2</content>
		     
	<content styleCode="bold">Efficacy of Ursodiol Administered at 14 mg/kg/day as a Once Daily Dose to PBC Patients</content>
                     </title>
                     <text>
                        <paragraph>
		     
	A second study conducted in Canada randomized 222 PBC patients to ursodiol, 14 mg/kg/day or placebo, administered as a once daily dose in a double-blind manner during a two-year period. At two years, a statistically significant (p&lt;0.001) difference between the two treatments (n=106 for the ursodiol tablets, USP 250 mg group and n=106 for the placebo group), in favor of ursodiol, was demonstrated in the following: reduction in the proportion of patients exhibiting a more than 50% increase in serum bilirubin; median percent decrease in bilirubin (-17.12% for the ursodiol tablets, USP 250 mg group vs. +20.00% for the placebo group), transaminases (-40.54% for the ursodiol tablets, USP 250 mg group vs. +5.71% for the placebo group) and alkaline phosphatase (-47.61% for the ursodiol tablets, USP 250 mg group vs. -5.69% for the placebo group); incidence of treatment failure; and time to treatment failure. The definition of treatment failure included: discontinuing the study for any reason; a total serum bilirubin level greater than or equal to 1.5 mg/dl or increasing to a level equal to or greater than two times the baseline level; and the development of ascites or encephalopathy. Evaluation of patients at 4 years or longer was inadequate due to the high dropout rate (n=10 withdrew from the ursodiol tablets, USP 250 mg group vs. n=15 from the placebo group) and small number of patients. Therefore, death, need for liver transplantation, histological progression by two stages or to cirrhosis, development of varices, ascites or encephalopathy, marked worsening of fatigue or pruritus, inability to tolerate the drug, doubling of serum bilirubin and voluntary withdrawal were not assessed. </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1a58579f-e693-44e9-b054-7fbaeb816ad0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.3</content>
		     
	<content styleCode="bold">Efficacy of </content>
                        <content styleCode="bold">Ursodiol </content>
                        <content styleCode="bold">tablet</content>
                        <content styleCode="bold">s, USP 250 mg</content>
                        <content styleCode="bold"> Administered in Twice a Day Versus Four Times a Day</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">Divided Dosing Schedules to PBC Patients</content>
                     </title>
                     <text>
                        <paragraph>
		     
	A randomized, two-period crossover study in fifty PBC patients compared efficacy of ursodiol tablets, USP 250 mg in twice a day versus four times a day divided dosing schedules in 50 patients for 6 months in each crossover period.  Mean percent changes from baseline in liver test results and Mayo risk score (n=46) and serum enrichment with UDCA (n=34) were not statistically significant with any dosage at any time interval. This study demonstrated that UDCA (13 to 15 mg/kg/day) given twice a day is equally effective to UDCA given four times a day. In addition, ursodiol tablets, USP 250 mg was given as a single versus three times a day dosing schedules in 10 patients. Due to the small number of patients in this arm of the study, it was not possible to conduct statistical comparisons between these regimens.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="0d33cc08-3e9b-45bd-9628-1fd6c4eed4c2"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
		     
	<content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <effectiveTime value="20180629"/>
               <component>
                  <section>
                     <id root="55bc4b03-0ffc-4573-9709-17ee4d12cd3e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">16.1</content>
		     
	<content styleCode="bold">Ursodiol </content>
                        <content styleCode="bold">t</content>
                        <content styleCode="bold">ablet</content>
                        <content styleCode="bold">s, USP 250 mg</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Each ursodiol tablets, USP 250 mg elliptical, biconvex, film-coated tablet, white, engraved with "URS785", contains 250 mg of ursodiol. Available in bottles of 100 tablets (NDC 0591-2998-01). </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section ID="_16_2_Ursodiol_tablets_">
                     <id root="1188193e-b3e0-4c15-95ba-2f9dad79ac75"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">16.2</content>
		     
	<content styleCode="bold">Ursodiol tablets, U</content>
                        <content styleCode="bold">SP 500</content>
                        <content styleCode="bold"> mg</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Each ursodiol tablets, USP 500 mg elliptical, biconvex, scored, film-coated tablet, white, engraved with "URS790", contains 500 mg of ursodiol. Available in bottles of 100 tablets (NDC 0591-3005-01). </paragraph>
                        <paragraph>
		     
	Store at 20°C to 25°C (68°F to 77°F).  Dispense in a tight container.</paragraph>
                        <paragraph>
		     
	Half-tablets (scored ursodiol tablets, USP 500 mg broken in half) maintain acceptable quality for up to 28 days when stored in the current packaging (bottles) at 20ºC to 25ºC (68ºF to 77ºF). Due to the bitter taste, the halved segments should be stored separately from the whole tablets <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Scoring_the">Dosage and Administration (2.3)</linkHtml>
                           </content>
                           <content styleCode="italics">]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a0f1bcc0-f8d7-46f2-b0c1-a279f99c4302"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
		     
	<content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <effectiveTime value="20180629"/>
               <component>
                  <section>
                     <id root="2f88c978-6638-4dbc-b8b2-1628d8e6c58c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">17.1</content>
		     
	<content styleCode="bold">Appropriate Treatments</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Patients with the following conditions should be instructed to receive appropriate management measures: variceal bleeding, hepatic encephalopathy, ascites, in need of an urgent liver transplant or hepatic function deterioration <content styleCode="italics">[see</content> <content styleCode="italics">
                              <linkHtml href="#_5_WARNINGS_AND">Warnings and Precautions (5)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. </paragraph>
                        <paragraph>
		     
	Caution has to be exercised to maintain the bile flow of the patients taking ursodiol.</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="83f47779-3ff7-4029-804a-80d57c026ce8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>
                        <content styleCode="bold">17.2</content>
		     
	<content styleCode="bold">Drug Interactions</content>
                     </title>
                     <text>
                        <paragraph>
		     
	Patients should be informed that absorption of ursodiol tablets, USP 250 mg and 500 mg may be reduced if they are taking bile acid sequestering agents, such as cholestyramine and colestipol, aluminum-based antacids, or drugs known to alter the metabolism of cholesterol <content styleCode="italics">[see</content> <content styleCode="italics">
                              <linkHtml href="#_7_Drug_Interactions">Drug Interactions (7)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Manufactured by: <br/>Confab Laboratories<br/>St-Hubert (Quebec) CANADA</paragraph>
                        <paragraph>Distributed by: <br/>Actavis Pharma, Inc.<br/>Parsippany, NJ 07054 USA</paragraph>
                        <paragraph>Revised: June 2018</paragraph>
                     </text>
                     <effectiveTime value="20180629"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="2a930b7f-ab71-4d3e-9ba7-01b9d50fbf21"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel</content>
                  </paragraph>
                  <paragraph>NDC 0591-2998-01</paragraph>
                  <paragraph>Ursodiol Tablets, USP </paragraph>
                  <paragraph>250 mg</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000002"/>
                  </paragraph>
               </text>
               <effectiveTime value="20180629"/>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>Principal Display Panel

NDC 0591-2998-01
Ursodiol Tablets, USP 
250 mg
100 Tablets
Rx only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ursodiol-tablets-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="a7a5d6d4-f4bf-41f9-814c-da94160b1c45"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Principal Display Panel</content>
                  </paragraph>
                  <paragraph>NDC 0591-3005-01</paragraph>
                  <paragraph>Ursodiol Tablets, USP </paragraph>
                  <paragraph>500 mg</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000003"/>
                  </paragraph>
               </text>
               <effectiveTime value="20180629"/>
               <component>
                  <observationMedia ID="MM03000003">
                     <text>Principal Display Panel

NDC 0591-3005-01
Ursodiol Tablets, USP 
500 mg
100 Tablets
Rx only
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ursodiol-tablets-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>